28 July 2015
LET’S TALK ABOUT KENNEL COUGH
A new YouGov survey on kennel cough, also known as Canine Infectious Respiratory Disease (CIRD), commissioned by MSD Animal Health, the manufacturers of NOBIVAC® KC, has revealed that 41% of owners said their vet had not discussed kennel cough vaccination at the time their dog was vaccinated. A further 21% could not recall if their vet did or did not talk to them about kennel cough vaccination. Yet 43% of owners whose dog had contracted kennel cough considered the impact on the health of their dog to be severe.
The 2015 YouGov MSD Animal Health NOBIVAC® KC Survey of dog owners was a repeat of the same survey carried out in 2009 and 2012 so the figures revealed some useful comparisons for vets to consider, particularly in terms of gaps in communications between vets and owners, leading to misinformed perceptions.
While awareness of the disease is high (88% of dog owners surveyed), 82% of respondents continue to feel that a dog is most likely to catch it in a boarding kennel. 41% of respondents were also unaware that kennel cough requires a vaccine which is additional to the normal annual booster.
Amanda Melvin, Senior Product Manager for NOBIVAC® KC, at MSD Animal Health comments: “Our survey clearly shows a communications gap, and an opportunity missed, between vets and dog owners. While their clients are aware of the severity of the disease, vets are missing out on the chance to talk to owners about kennel cough when they do provide core vaccinations and boosters. This is a great opportunity for veterinary nurses to play a role in informing clients on the importance of kennel cough vaccination. Research that we completed in 2009 revealed that an incredible 90% of vets had seen cases of kennel cough in the last year which suggests that it just isn’t being talked about enough. Veterinary nurses can help fill the communications gap and avoid the risk of a disease that is very distressing for both the dog and the owner.”
Kennel cough is one of the most common significant infectious syndromes of dogs in the UK, accounting for an estimated 44,000 cases seen in practice per year1 and exposure to respiratory pathogens can occur anywhere dogs mix. In a survey of practices 41% of recent cases were suspected to have been the result of exposure to outside kennels2 yet half of all dog owners did not recall advice to vaccinate against kennel cough when boarding their dogs3.
1.Estimate of affected dogs in practice based on extrapolation of CICADA UK survey disease reports to April 2015. 2.Suspected source of outbreaks reported during telephone interviews with veterinary practices during November 2009. 3.YouGov survey of dog owners, March 2012.
About MSD Animal Health Today's MSD is a global healthcare leader working to help the world be well. MSD Animal Health, a division of Merck & Co., Inc., Kenilworth, NJ, USA., is the global animal health business unit of MSD. Through its commitment to the Science of Healthier Animals™, MSD Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.msd-animal-health.com or connect with us on LinkedIn.
MSD forward-Looking Statement This presentation includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of MSD’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forwardlooking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; MSD’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of MSD’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. MSD undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in MSD’s 2014 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).